Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients

Aliment Pharmacol Ther. 2023 Mar;57(5):577-578. doi: 10.1111/apt.17340.

Authors

Yen-Chun Liu^{1

2}, Wen-Juei Jeng^{1

2}

Affiliations

¹ College of Medicine, Chang Gung University, Taipei, Taiwan.
² Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan.

PMID: 36786455
DOI: 10.1111/apt.17340

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents / therapeutic use
Hepatitis B Surface Antigens
Hepatitis B, Chronic* / drug therapy
Humans

Substances

Hepatitis B Surface Antigens
Antiviral Agents